Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05136703 · ClinicalTrials.gov registry record · NA
Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)
A NA study of Depression and Inflammation, sponsored by Florida International University.
- Recruiting
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 2
- Study locations
NCT05136703: Recruiting NA study of Depression and Inflammation, sponsored by Florida International University.
NCT05136703 is a NA study of Depression and Inflammation that is actively recruiting participants, run by Florida International University. The registered enrollment target is 150 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (81% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05136703, a NA study of Depression and Inflammation, is actively recruiting participants, sponsored by Florida International University.
- RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this randomized controlled trial is to understand how a cognitive-behavioral treatment (a form of psychological treatment) for depression changes the gut microbiome (micro-organisms that regulate the health of the gut), immune system, and the brain functioning in people living with HIV.
Primary Outcome
Measured by functional Magnetic Resonance Imaging (fMRI)
Conditions Studied
Interventions
- BEHAVIORAL Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD)
- BEHAVIORAL Antiretroviral Therapy (ART) Adherence Counseling
Study Locations (2)
Florida
- University of Miami Neuroimaging Facility - Coral Gables
- Care Resource - Midtown Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2022-08-30 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What NCT05136703 shows while recruiting
NCT05136703 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (81% lower).
The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD) is the first listed.
NCT05136703 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05136703 about?
NCT05136703 is a clinical study titled "Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)". The purpose of this randomized controlled trial is to understand how a cognitive-behavioral treatment (a form of psychological treatment) for depression changes the gut microbiome (micro-organisms that regulate the health of the gut), immune system, and the brain functioning in people living with HI...
What is the current status of trial NCT05136703?
This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2022-08-30. Estimated completion is 2027-12-31.
What conditions does trial NCT05136703 study?
This clinical trial studies the following conditions: Depression, Inflammation, HIV-1-infection.
What interventions are being tested in trial NCT05136703?
The interventions under investigation include: Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD) (BEHAVIORAL), Antiretroviral Therapy (ART) Adherence Counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT05136703?
This trial is sponsored by Florida International University, which has 89 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05136703 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05136703's enrollment target sits among peer trials
150 249th of 679 higher than 416 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
Cold and Heat Investigation to Lower Levels of Depression
RECRUITING · NA
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy